Analysis
ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million shares at $17 apiece, above the low end of its marketed range, for gross proceeds of roughly $446.3 million, according to Reuters and BioPharma Dive. Shares began trading on the Nasdaq Global Select Market on Sept. 25 under the ticker ADRX.
A concurrent private placement sold about $89 million of stock directly to AbbVie, bringing total proceeds tied to the offering to roughly $535.2 million.
ADARx is a late-stage clinical-stage biotech developing siRNA (small interfering RNA) therapeutics -- drugs that silence disease-causing genes rather than targeting proteins directly -- aimed at complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic diseases. The company is led by CEO and co-founder Zhen Li, a veteran of both Arrowhead Pharmaceuticals and Merck, and uses proprietary delivery platforms it calls PLR (Preeminent Liver RNA) and SPE to get siRNA drugs into target tissue.
“A concurrent private placement sold about $89 million of stock directly to AbbVie, bringing total proceeds tied to the offering to roughly $535.2 million.”
Funding History And The AbbVie Relationship
Before this IPO, ADARx's largest private round was a $200 million Series C -- almost double its two previous Series B rounds combined -- backed by institutional investors including BlackRock, T. Rowe Price and Venrock alongside existing backers Ascenta Capital, Lilly Asia Ventures, OrbiMed and SR One Capital Management. ADARx also holds a collaboration and license-option agreement with AbbVie covering siRNA therapeutics in neuroscience, immunology and oncology -- the same partner now buying $89 million of stock directly alongside the public offering, a structure that ties ADARx's public debut closely to a single large pharma relationship rather than a diversified customer or partner base.
Competitive Landscape
ADARx is entering public markets in a category two much larger, already-public rivals dominate. Alnylam Pharmaceuticals is the field's clear leader, with multiple approved siRNA drugs on the market and a valuation in the tens of billions. Arrowhead Pharmaceuticals, where ADARx's own CEO previously worked, has several siRNA candidates in late-stage trials and existing partnerships with Takeda and others. Ionis Pharmaceuticals works the adjacent antisense-oligonucleotide approach to the same silencing goal. ADARx's pitch to public investors is that its delivery platform reaches tissues -- like the CNS -- that first-generation siRNA drugs struggle to hit, but it has no approved product yet, meaning its entire near-term valuation rests on clinical trial readouts still to come.
The Numbers In Context
At $17 a share and 26.25 million shares sold, ADARx's IPO proceeds are modest next to the two other US listings competing for the same week's attention -- Nscale's $3.36 billion pre-IPO convertible round and Oura's roughly $2.1 billion targeted raise.
But $446.3 million is a substantial clinical-stage biotech IPO by historical standards, in a year where the broader US IPO market has already priced more than 109 deals worth $146.5 billion through mid-September.
What the pricing doesn't tell investors: ADARx has no approved drugs generating revenue, so the stock's near-term performance will trade almost entirely on clinical trial data readouts rather than earnings -- the same binary risk profile that has produced sharp drops for clinical-stage biotechs on a single disappointing trial result. The AbbVie side-deal also means a meaningful chunk of ADARx's committed capital comes from one partner with its own strategic interest in the company's pipeline, not purely independent public-market demand.
For biotech-focused funds, ADARx's debut is a read on whether public markets will keep funding pre-revenue RNAi science at current valuations, or whether September's fall IPO window cools once the fresh-listing backlog clears.